Products for Research Use Only

Dolasetron-d5

CAT: 0804-HY-B0750S1Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B0750S1Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Dolasetron-d5 is deuterated labeled Dolasetron. Dolasetron (MDL-73147) is a 5-HT3 receptor antagonist with potential for treatment of chemotherapy-induced nausea and vomiting.
Product Name Alternative
MDL-73147-d5
UNSPSC
12352005
Target
5-HT Receptor; Isotope-Labeled Compounds
Type
Isotope-Labeled Compounds
Related Pathways
GPCR/G Protein; Neuronal Signaling; Others
Applications
Cancer-programmed cell death
Field of Research
Cancer
Solubility
10 mM in DMSO
Smiles
O=C(C1=C([2H])NC2=C1C([2H])=C([2H])C([2H])=C2[2H])O[C@@H]3C[C@@](CC4C5)([H])[N@](CC4=O)[C@@]5([H])C3
Molecular Formula
C19H15D5N2O3
Molecular Weight
329.40
References & Citations
[1]Faria C, et al. Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis. Am Health Drug Benefits. 2014 Jan;7 (1) :50-8.|[2]Schwartzberg L, et al. Pooled analysis of phase III clinical studies of palonosetron versus ondansetron, dolasetron, and granisetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) . Support Care Cancer. 2014 Feb;22 (2) :469-77.|[3]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53 (2) :211-216.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported